Imipramine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Imipramine

Examples of brand names: Tofranil [DE]

ATC code: N06AA02

Main use (for orientation): Depression

Documented research summary

A preclinical CBD title is recorded, but its findings cannot be reliably extracted without sufficient accessible result text. No established clinical pair effect.

Uncertainties and limitations

PMID25379896 retrieved without an abstract; the title is insufficient to determine the direction/magnitude of a combination effect. UK label currently accessible, revision 2018; no CYP contributions invented.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Evidence gap

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Insufficient pair-specific data

Mechanism / drug context: Imipramine and its active desipramine metabolite; CYP2D6, central/cardiac effects.

Type of supporting material: Medicine information and documented individual review; no positive pair trial

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Oral imipramine hydrochloride; active substance with an active desipramine metabolite.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [CA_L_D0098]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: Imipramine Tablets BP10mg – Summary of Product Characteristics [CA_L_D0098]

Source role [CA_P_25379896]: Open full-text question

Statement supported: Preclinical CBD/imipramine title; no reliable effect extraction from the title alone.

Source: Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdala. [CA_P_25379896]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: Complete saved individual review, label assessment, literature screening, conclusion and uncertainties read. Original information was selectively rechecked by section; no complete revalidation of all prescribing information or full texts claimed. PMID25379896: original abstract/full text not sufficiently accessible; finding unresolved.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[CA_L_D0098] Imipramine Tablets BP10mg – Summary of Product Characteristics

Original source / bibliographic reference

Authors: Noumed Life Sciences Limited

Year: 2018

Source type: Official SmPC (MHRA)

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_25379896] Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdala.

Original source / bibliographic reference

Authors: Réus GZ, Stringari RB, Ribeiro KF, Luft T, Abelaira HM, Fries GR, Aguiar BW, Kapczinski F, Hallak JE, Zuardi AW, Crippa JA, Quevedo J.

Year: 2011

Source type: Journal Article

DOI: 10.1111/j.1601-5215.2011.00579.x

PMID: 25379896

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility